BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34763650)

  • 21. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
    Aggarwal S; John S; Sapra L; Sharma SC; Das SN
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential.
    Bürkel F; Jost T; Hecht M; Heinzerling L; Fietkau R; Distel L
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
    Firat E; Niedermann G
    Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr.
    Fedrigo CA; Grivicich I; Schunemann DP; Chemale IM; dos Santos D; Jacovas T; Boschetti PS; Jotz GP; Braga Filho A; da Rocha AB
    Radiat Oncol; 2011 Nov; 6():156. PubMed ID: 22077956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines.
    Sak A; Groneberg M; Stuschke M
    Int J Radiat Biol; 2019 Sep; 95(9):1205-1219. PubMed ID: 31287365
    [No Abstract]   [Full Text] [Related]  

  • 26. Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy.
    Zhuang W; Li B; Long L; Chen L; Huang Q; Liang ZQ
    Brain Res; 2011 Jan; 1371():7-15. PubMed ID: 21108935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
    Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
    Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death.
    Chen GG; Sin FL; Leung BC; Ng HK; Poon WS
    J Cell Physiol; 2005 Apr; 203(1):127-32. PubMed ID: 15493013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.
    Facchino S; Abdouh M; Chatoo W; Bernier G
    J Neurosci; 2010 Jul; 30(30):10096-111. PubMed ID: 20668194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mangiferin induces radiosensitization in glioblastoma cells by inhibiting nonhomologous end joining.
    Mu F; Liu T; Zheng H; Xie X; Lei T; He X; Du S; Tong R; Wang Y
    Oncol Rep; 2018 Dec; 40(6):3663-3673. PubMed ID: 30272350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
    Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
    Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitor.
    Kodym E; Kodym R; Chen BP; Chen DJ; Morotomi-Yano K; Choy H; Saha D
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):187-93. PubMed ID: 17707272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-dependent protein kinase catalytic subunit inhibitor reverses acquired radioresistance in lung adenocarcinoma by suppressing DNA repair.
    Li Y; Li H; Peng W; He XY; Huang M; Qiu D; Xue YB; Lu L
    Mol Med Rep; 2015 Jul; 12(1):1328-34. PubMed ID: 25815686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation.
    Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z
    J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
    Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
    Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.